1
|
Uchiyama H, Barut BA, Mohrbacher AF,
Chauhan D and Anderson KC: Adhesion of human myeloma-derived cell
lines to bone marrow stromal cells stimulates interleukin-6
secretion. Blood. 82:3712–3720. 1993.PubMed/NCBI
|
2
|
Chauhan D, Uchiyama H, Akbarali Y,
Urashima M, Yamamoto K, Libermann TA and Anderson KC: Multiple
myeloma cell adhesion-induced interleukin-6 expression in bone
marrow stromal cells involves activation of NF-kappa B. Blood.
87:1104–1112. 1996.PubMed/NCBI
|
3
|
Dankbar B, Padro T, Leo R, Feldmann B,
Kropff M, Mesters RM, Serve H, Berdel WE and Kienast J: Vascular
endothelial growth factor and interleukin-6 in paracrine
tumor-stromal cell interactions in multiple myeloma. Blood.
95:2630–2636. 2000.PubMed/NCBI
|
4
|
Gupta D, Treon SP, Shima Y, Hideshima T,
Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D,
Schlossman RL, Richardson P, Ralph P, Wu L, Payvandi F, Muller G,
Stirling DI and Anderson KC: Adherence of multiple myeloma cells to
bone marrow stromal cells upregulates vascular endothelial growth
factor secretion: therapeutic applications. Leukemia. 15:1950–1961.
2001. View Article : Google Scholar
|
5
|
Druckmann R and Rohr UD: IGF-1 in
gynaecology and obstetrics. Maturitas. 41:S65–S83. 2002. View Article : Google Scholar
|
6
|
Brokaw J, Katsaros D, Wiley A, Lu L, Su D,
Sochirca O, De la Longrais IA, Mayne S, Risch H and Yu H: IGF-I in
epithelial ovarian cancer and its role in disease progression.
Growth Factors. 25:346–354. 2007. View Article : Google Scholar : PubMed/NCBI
|
7
|
Holly J and Perks C: The role of
insulin-like growth factor binding proteins. Neuroendocrinology.
83:154–160. 2006. View Article : Google Scholar : PubMed/NCBI
|
8
|
Jemal A, Thun MJ, Ries LA, Howe HL, Weir
HK, Center MM, Ward E, Wu XC, Eheman C, Anderson R, Ajani UA,
Kohler B and Edwards BK: Annual report to the nation on the status
of cancer, 1975–2005, featuring trends in lung cancer, tobacco use,
and tobacco control. J Natl Cancer Inst. 100:1672–1694. 2008.
|
9
|
Rafii A, Mirshahi P, Poupot M, Faussat AM,
Simon A, Ducros E, Mery E, Couderc B, Lis R, Capdet J, Bergalet J,
Querleu D, Dagonnet F, Fournié JJ, Marie JP, Pujade-Lauraine E,
Favre G, Soria J and Mirshahi M: Oncologic trogocytosis of an
original stromal cell induces chemoresistance of ovarian tumours.
PLoS One. 3:e38942008. View Article : Google Scholar : PubMed/NCBI
|
10
|
Sako A, Kitayama J, Yamaguchi H, Kaisaki
S, Suzuki H, Fukatsu K and Fujii S: Vascular endothelial growth
factor synthesis by human omental mesothelial cells is augmented by
fibroblast growth factor-2: possible role of mesothelial cell on
the development of peritoneal metastasis. J Surg Res. 115:113–120.
2003. View Article : Google Scholar
|
11
|
Wilson AP: Mesothelial cells stimulate the
anchorage-independent growth of human ovarian tumour cells. Br J
Cancer. 59:876–882. 1989. View Article : Google Scholar : PubMed/NCBI
|
12
|
Pasquet M, Golzio M, Mery E, Rafii A,
Benabbou N, Mirshahi P, Hennebelle I, Bourin P, Allal B, Teissie J,
Mirshahi M and Couderc B: Hospicells (ascites-derived stromal
cells) promote tumori-genicity and angiogenesis. Int J Cancer.
126:2090–2101. 2010.PubMed/NCBI
|
13
|
Lis R, Capdet J, Mirshahi P, Lacroix-Triki
M, Dagonnet F, Klein C, Mirshahi M, Fournié JJ, Rafii A and Poupot
M: Oncologic trogocytosis with Hospicells induces the expression of
N-cadherin by breast cancer cells. Int J Oncol. 37:1453–1461.
2010.PubMed/NCBI
|
14
|
Martinet L, Poupot R, Mirshahi P, Rafii A,
Fournié JJ, Mirshahi M and Poupot M: Hospicells derived from
ovarian cancer stroma inhibit T-cell immune responses. Int J
Cancer. 126:2143–2152. 2010.PubMed/NCBI
|
15
|
Castells M, Thibault B, Mery E, Golzio M,
Pasquet M, Hennebelle I, Bourin P, Mirshahi M, Delord JP, Querleu D
and Couderc B: Ovarian ascites-derived Hospicells promote
angiogenesis via activation of macrophages. Cancer Lett. 326:59–68.
2012. View Article : Google Scholar : PubMed/NCBI
|
16
|
Ducros E, Berthaut A, Mirshahi SS, Faussat
AM, Soria J, Agarwal MK and Mirshahi M: Aldosterone modifies
hemostasis via upregulation of the protein-C receptor in human
vascular endothelium. Biochem Biophys Res Commun. 373:192–196.
2008. View Article : Google Scholar : PubMed/NCBI
|
17
|
Smith JA, Ngo H, Martin MC and Wolf JK: An
evaluation of cytotoxicity of the taxane and platinum agents
combination treatment in a panel of human ovarian carcinoma cell
lines. Gynecol Oncol. 98:141–145. 2005. View Article : Google Scholar : PubMed/NCBI
|
18
|
Kucerova L and Skolekova S: Tumor
microenvironment and the role of mesenchymal stromal cells.
Neoplasma. 60:1–10. 2013. View Article : Google Scholar : PubMed/NCBI
|
19
|
Beauchamp MC, Yasmeen A, Knafo A and
Gotlieb WH: Targeting insulin and insulin-like growth factor
pathways in epithelial ovarian cancer. J Oncol. 2010:2570582010.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Belfiore A and Frasca F: GF and insulin
receptor signaling in breast cancer. J Mammary Gland Biol
Neoplasia. 13:381–406. 2008. View Article : Google Scholar : PubMed/NCBI
|
21
|
Weiss JM, Huang WY, Rinaldi S, Fears TR,
Chatterjee N, Chia D, Crawford ED, Kaaks R and Hayes RB: IGF-I and
IGFBP-3: risk of prostate cancer among men in the Prostate, Lung,
Colorectal and Ovarian Cancer Screening Trial. Int J Cancer.
121:2267–2273. 2007. View Article : Google Scholar : PubMed/NCBI
|
22
|
Gotlieb WH, Bruchim I, Gu J, Shi Y,
Camirand A, Blouin MJ, Zhao Y and Pollak MN: Insulin-like growth
factor receptor I targeting in epithelial ovarian cancer. Gynecol
Oncol. 100:389–396. 2006. View Article : Google Scholar : PubMed/NCBI
|
23
|
Grivennikov S and Karin M: Autocrine IL-6
signaling: a key event in tumorigenesis? Cancer Cell. 13:7–9. 2008.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Gest C, Mirshahi P, Li H, Pritchard LL,
Joimel U, Blot E, Chidiac J, Poletto B, Vannier JP, Varin R,
Mirshahi M, Cazin L, Pujade-Lauraine E, Soria J and Soria C:
Ovarian cancer: Stat3, RhoA and IGF-IR as therapeutic targets.
Cancer Lett. 317:207–217. 2012. View Article : Google Scholar : PubMed/NCBI
|
25
|
Walther W and Stein U: Therapeutic genes
for cancer gene therapy. Mol Biotechnol. 13:21–28. 1999. View Article : Google Scholar : PubMed/NCBI
|
26
|
Kang Y and Perry RR: Effect of
alpha-interferon on P-glycoprotein expression and function and on
verapamil modulation of doxorubicin resistance. Cancer Res.
54:2952–2958. 1994.PubMed/NCBI
|
27
|
Stein U, Walther W, Lemm M, Naundorf H and
Fichtner I: Development and characterisation of novel human
multidrug resistant mammary carcinoma lines in vitro and in vivo.
Int J Cancer. 72:885–891. 1997. View Article : Google Scholar : PubMed/NCBI
|
28
|
Hu C, Li H, Li J, Zhu Z, Yin S, Hao X, Yao
M, Zheng S and Gu J: Analysis of ABCG2 expression and side
population identifies intrinsic drug efflux in the HCC cell line
MHCC-97L and its modulation by Akt signaling. Carcinogenesis.
29:2289–2297. 2008. View Article : Google Scholar : PubMed/NCBI
|
29
|
Fischer B, Frei C, Moura U, Stahel R and
Felley-Bosco E: Inhibition of phosphoinositide-3 kinase pathway
down regulates ABCG2 function, and sensitizes malignant pleural
mesothelioma to chemotherapy. Lung Cancer. 78:23–29. 2012.
View Article : Google Scholar : PubMed/NCBI
|
30
|
Zatelli MC, Minoia M, Molè D, Cason V,
Tagliati F, Margutti A, Bondanelli M, Ambrosio MR and degli Uberti
E: Growth hormone excess promotes breast cancer chemoresistance. J
Clin Endocrinol Metab. 94:3931–3938. 2009. View Article : Google Scholar : PubMed/NCBI
|
31
|
Johnatty SE, Beesley J, Paul J, Fereday S,
Spurdle AB, Webb PM, Byth K and Marsh S: ABCB1 (MDR1) polymorphisms
and progression-free survival among women with ovarian cancer
following paclitaxel/carboplatin chemotherapy. Clin Cancer Res.
14:5594–5601. 2008. View Article : Google Scholar : PubMed/NCBI
|
32
|
Siddik ZH: Cisplatin: mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
33
|
Wang D and Lippard SJ: Cellular processing
of platinum anticancer drugs. Nat Rev Drug Discov. 4:307–320. 2005.
View Article : Google Scholar : PubMed/NCBI
|
34
|
Chen HHW and Kuo MT: Role of glutathione
in the regulation of cisplatin resistance in cancer chemotherapy.
Met Based Drugs. 2010:1–7. 2010. View Article : Google Scholar : PubMed/NCBI
|
35
|
Grothey A, Voigt W, Schöber C, Müller T,
Dempke W and Schmoll HJ: The role of insulin-like growth factor I
and its receptor in cell growth, transformation, apoptosis, and
chemoresistance in solid tumors. J Cancer Res Clin Oncol.
125:166–173. 1999. View Article : Google Scholar : PubMed/NCBI
|